Navigation Links
Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Date:1/29/2008

41

Interest expense (73) (79) (273) (348) (1,430)

Change in fair value

of warrant liability 4 - (23) (149) (454)

Other expense - - (1,180) - (1,180)

Loss before tax

benefit (17,790) (11,773) (46,345) (41,167) (125,529)

Income tax benefit - - - - 695

Net loss (17,790) (11,773) (46,345) (41,167) (124,834)

Deemed dividend - - (19,424) - (19,424)

Preferred stock accretion (37) - (159) (351) (802)

Net loss attributable

to common

stockholders $(17,827) $ (11,773) $(65,928) $(41,518) $(145,060)

Net loss attributable

to common stockholders

per common share -

basic and diluted $ (19.77) $(0.53) $(89.58) $(3.14)

Weighted-average

common shares

outstanding - basic

and diluted 901,748 22,343,974 735,967 13,235,755

See accompanying notes to consolidated financial statements

Table 2

Amicus Therapeutics, Inc.

Reconciliation of GAAP to non-GAAP Measures for the
Statement of Operations Information for Three Months Ended December 31, 2007
(Unaudited)

(In thousands, except share and per share amounts)

Preferred

Stock Stock GAAP as

Non-GAAP Accretion Compensation Reported

Income Statement

Classifications:

Revenue $1,784 $1,784

Research and development (9,235) $- $(435) (9,670)

General and administrative (4,
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
2. Amicus Therapeutics to Host R&D Day
3. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
4. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
5. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
6. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
7. Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
8. Cell Therapeutics, Inc. (CTI) Shareholders Authorize Share Increase at Special Meeting of Shareholders
9. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
10. Nile Therapeutics Appoints Gregory W. Schafer to Board of Directors
11. Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... ALBANY, New York , August 1, 2014 /PRNewswire/ ... published by Transparency Market Research "Biophotonics Market - Global ... - 2020," the market was valued at USD 25.16 ... 50.20 billion by 2020, growing at a CAGR of ... full Biophotonics Market Report at  http://www.transparencymarketresearch.com/biophotonics-market.html ...
(Date:8/1/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... AND GLOBAL MARKETS , that the global market RNA ... to nearly $38.8 billion by 2018, with a five-year ... delivery category, the fastest moving segment of the market, ... field of RNAi therapeutics has shown tremendous growth and ...
(Date:8/1/2014)... Testing the mechanical properties of microtissues ... embryonic development. How and why embryonic stem ... distinct tissues is important because abnormalities can lead ... Melissa Kinney, and Rabbia Saeed worked from the ... to control many aspects of embryo development. ...
(Date:7/31/2014)... July 31, 2014 Today BioSpace , the leading life ... map campaign spotlighting the life sciences community in Illinois ... Kansas , Michigan , Minnesota ... Ohio and Wisconsin . ... percent of all job postings on BioSpace originating in this region in ...
Breaking Biology Technology:Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 2Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 3Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 4Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR 2Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR 3Study Links Biomechanics and Gene Expression in Stem Cells 2Midwest Biotech Leaders Featured On BioSpace Map 2
... April 20 Santaris Pharma announced today,promising ... vivo activity of microRNA-targeted,therapeutics against cancer developed ... Acid (LNA) Drug Platform. In both in ... targeted LNA-antimiR(R),s demonstrated outstanding,recognition and inhibition of ...
... Group of AdvisorsSAN DIEGO, April 20 Trius Therapeutics, ... Board, naming Donald H. Batts, MD, FACP, FIDSA, and ... members of the group of anti-infective thought leaders. ... Michigan State University and the Chief of Infectious ...
... Photonics , a joint team of researchers at CIC ... de Materiales of CSIC/UPV-EHU in San Sebastian (Spain), Harvard ... in Munich (Germany) reports an innovative method for controlling ... radio-frequency technology. The method opens the door for targeted ...
Cached Biology Technology:LNA-Based RNA oligonucleotides Potently Inhibit Cancer microRNAs 2Trius Appoints Don Batts and Ralph Corey to Clinical Advisory Board 2Bridging the gap in nanoantennas 2Bridging the gap in nanoantennas 3
(Date:8/1/2014)... than 10,000 reptile species have been recorded into ... living reptile species and classification, making the reptile ... the world, alongside bird and fish species. , ... would mark the year that reptiles would become ... Reptiles include snakes, lizards, turtles, crocodiles, tuataras and ...
(Date:8/1/2014)... marine mammals have officially named a species new ... sahulensis , according to the Wildlife Conservation Society ... the newly named species is the culmination of ... historical records, physical descriptions, and genetic data of ... from the coast of West Africa to the ...
(Date:8/1/2014)... The Journal of Nutrition Education and Behavior (JNEB) announces ... (GEM) awards, which were presented at the Society for ... Impact: Local to Global," in Milwaukee, Wisconsin, June 28 ... the authors of the best article and best GEM ... of the JNEB Journal Committee and Board of Editors. ...
Breaking Biology News(10 mins):Reptile Database surpasses 10,000 reptile species 2Reptile Database surpasses 10,000 reptile species 3Scientists name new species of cetacean: The Australian humpback dolphin 2Scientists name new species of cetacean: The Australian humpback dolphin 3
... In what amounted to a kind of ... data from 175 fields in Illinois, Wisconsin, and Minnesota shed ... the most troublesome weeds, the results also revealed some of ... and sweet corn yield in the Midwest. "Rather than ...
... News headlines are filled with discussion and debate ... Conference in Copenhagen. As expected, the majority ... focused on traditional environmental measures - regulations to ... etc. A new book Paradise Regained: The ...
... such as pomegranates, that contain anti-aromatase phytochemicals reduces the ... a study published in the January issue of ... Association for Cancer Research. Pomegranate is enriched ... as shown in this study, appear to be responsible ...
Cached Biology News:Sweet corn study provides large-scale picture of better fields 2Sweet corn study provides large-scale picture of better fields 3Global warming and other environmental dangers may be solved by unlikely source -- space technology 2Natural compounds in pomegranates may prevent growth of hormone-dependent breast cancer 2
... The epitope is specific for Kir2.1 ... other known protein.,SPECIES REACTIVITIES: The ... bovine, porcine and guinea pig. It ... mouse (17/19 residues) and chick (15/19 ...
... Glutamate is the main excitatory neurotransmitter ... had been considered to act only on ... kainate receptors that are involved in the ... been shown to regulate enzymes producing second ...
Polyclonal Antibody to TRIB1/ SKIP1/ Tribbles 1...
PMA (YPMA-1)...
Biology Products: